文 | 医药研究社靠大单品崛起的创新药企中,诺诚健华算是被低估的一个,近年该公司还是释放出一些“翻盘”信号。据最新财报,2025年1-6月,诺诚健华实现营业收入7.31亿元,同比增长74.26%;归母净亏损3009.14万元,上年同期亏损2.62亿元,同比收窄86.7%。不过,这样的业绩改善,基本由BTK(布鲁顿酪氨酸激酶)抑制剂奥布替尼(商品名:宜诺凯)驱动,报告期内该款产品销售额达到6.37...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.